Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345, an mRNA Vaccine Against RSV, Administered 12 Months Following a Primary Dose in Adults Aged ≥50 Years

Authors

Institutions

Publication Details

Journal
Clinical Infectious Diseases
Published
2025-09-24
DOI
https://doi.org/10.1093/cid/ciaf515
Citations
2
Primary Topic
Respiratory viral infections research
Type
article
Field-Weighted Citation Impact
2.71
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345, an mRNA Vaccine Against RSV, Administered 12 Months Following a Primary Dose in Adults Aged ≥50 Years

Sonia Stoszek, Christine A. Shaw, Caroline Reuter, Haiyu Zhou et al.
2 citations
Clinical Infectious Diseases
Respiratory viral infections research
2.71
article

Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345, an mRNA Vaccine Against RSV, Administered 12 Months Following a Primary Dose in Adults Aged ≥50 Years

Sonia Stoszek, Christine A. Shaw, Caroline Reuter, Haiyu Zhou, Avi Collins, Lauren Wilson, Archana Kapoor, Alana K. Simorellis, Jiejun Du, Jaya Goswami, Eleanor Wilson, Rakesh Dhar, José F. Cardona, Denise C. Hsu, Xiaowei Wang, Rituparna Das, Vinicius Righi, Jorge Caso, Lan Lan
article en
2 citations

Abstract

No abstract available for this paper.
Clinical Infectious Diseases
Florida Department of Health (US), Suncoast Clinical Research (US), Moderna Therapeutics (United States) (US)
Openalex Percentile: Top 9%
Respiratory viral infections research
2.71
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345, an mRNA Vaccine Against RSV, Administered 12 Months Following a Primary Dose in Adults Aged ≥50 Years — Sonia Stoszek, Christine A. Shaw, et al. · Clinical Infectious Diseases (2025) | TGRS Research Map | TGRS